Roche Roche muscling into melanoma with Tecentriq Swiss pharma looking to combine immunotherapy with already marketed drugs.
News Three's a crowd as Tecentriq approved in lung cancer Cancer immunotherapy approved in second line.
ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
News Samsung Bioepis files Herceptin biosimilar in EU South Korean firm trying to copy breast cancer blockbuster.
News NICE rejects Roche drug in follicular lymphoma NICE uncertain over survival data for Gazyvaro and bendamustine.
News Australia starts probe into AI infiltration of Medicare The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
